Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Trading banner 1
Trading banner 2
Trading banner 3
Trading banner 4
Trading banner 5
Trading banner 6
Trading banner 7
Trading banner 8
Trading banner 9
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell Adaptive Biotechnologies Corp (ADPT) – Adaptive Biotechnologies Corp Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

ADPT trades at $14.14, up 2.32% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growth from $179M in 2024 to $277M projected for 2025 and narrowing losses. However, negative profit margins and significant insider selling create headwinds. Analyst consensus remains positive with a $21.33 price target, representing 51% upside potential from current levels.
The stock presents a high-risk opportunity with improving operational trends but persistent profitability challenges. While revenue growth and earnings beats signal potential, substantial insider selling and negative cash flow require careful monitoring. The 51% upside to analyst targets suggests optimism, but execution risks and competitive pressures in biotechnology remain significant concerns for investors.
Read full analysis

Key Stats

  • Market Cap
    $2.18B
  • Sector
    Health
  • 3M Drawdown
    -35.47%
  • Enterprise Value
    $2.03B
  • Dividend Yield
    -
  • Typical Hold Time
    33 days
$14.14
52W Low: $7.36
01 May 2025
52W High: $20.46
24 Nov 2025

Adaptive Biotechnologies Corp (ADPT) is currently valued at a market capitalization of $2.18B, with an enterprise value of $2.03B. Over the past 52 weeks, Adaptive Biotechnologies Corp has traded between a low of $7.36 and a high of $20.46, highlighting its annual price range. Over the past three months, Adaptive Biotechnologies Corp has recorded a drawdown of -35.47%, reflecting recent price volatility. On average, investors hold Adaptive Biotechnologies Corp for approximately 33 days, indicating typical investor behavior on the platform.

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.


Technical Indicators
|
|
|
Overall Summary
Bearish (2)Neutral (11)Bullish (14)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $2.18B
  • Sector
    Health
  • 3M Drawdown
    -35.47%
  • Enterprise Value
    $2.03B
  • Dividend Yield
    -
  • Typical Hold Time
    33 days
$14.14
52W Low: $7.36
01 May 2025
52W High: $20.46
24 Nov 2025

Adaptive Biotechnologies Corp (ADPT) is currently valued at a market capitalization of $2.18B, with an enterprise value of $2.03B. Over the past 52 weeks, Adaptive Biotechnologies Corp has traded between a low of $7.36 and a high of $20.46, highlighting its annual price range. Over the past three months, Adaptive Biotechnologies Corp has recorded a drawdown of -35.47%, reflecting recent price volatility. On average, investors hold Adaptive Biotechnologies Corp for approximately 33 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!